Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
Abstract CD19‐directed chimeric antigen receptor (CAR)‐T cell therapy has become a standard treatment for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). While the benefits of CAR‐T cell treatment are clear in the general patient population, there remains a relative scarcity of real‐w...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | HemaSphere |
| Online Access: | https://doi.org/10.1002/hem3.54 |
| _version_ | 1797234735389343744 |
|---|---|
| author | Philipp Berning Evgenii Shumilov Markus Maulhardt Hristo Boyadzhiev Andrea Kerkhoff Simon Call Christian Reicherts Anna O. Saidy Enver Aydilek Michèle Hoffmann Urban Novak Michael Daskalakis Norbert Schmitz Matthias Stelljes Gerald Wulf Ulrike Bacher Georg Lenz Thomas Pabst |
| author_facet | Philipp Berning Evgenii Shumilov Markus Maulhardt Hristo Boyadzhiev Andrea Kerkhoff Simon Call Christian Reicherts Anna O. Saidy Enver Aydilek Michèle Hoffmann Urban Novak Michael Daskalakis Norbert Schmitz Matthias Stelljes Gerald Wulf Ulrike Bacher Georg Lenz Thomas Pabst |
| author_sort | Philipp Berning |
| collection | DOAJ |
| description | Abstract CD19‐directed chimeric antigen receptor (CAR)‐T cell therapy has become a standard treatment for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). While the benefits of CAR‐T cell treatment are clear in the general patient population, there remains a relative scarcity of real‐world evidence regarding its efficacy and toxicity in patients (pts) aged ≥70 years with DLBCL. We conducted a multicenter retrospective analysis including 172 r/r DLBCL pts with CAR‐T cell treatment, axicabtagene ciloleucel or tisagenlecleucel, between 2019 and 2023 at three tertiary centers. Pts were grouped by age at CAR‐T infusion (<70 vs. ≥70 years). Subsequently, descriptive and survival analyses, including propensity score matching, were performed to compare outcomes between both age groups. We identified 109 pts aged <70 and 63 pts aged ≥70 years. Overall response rates for both age groups were comparable (77.7% vs. 78.3%; p = 0.63). With a median follow‐up of 8.3 months, median progression‐free survival was 10.2 months (95% confidence interval [CI]: 6.5–21.8) and 11.1 months (95% CI: 4.9–NR) (p = 0.93) for both cohorts. Median overall survival reached 21.8 months (95% CI: 11.8–NR) and 34.4 months (95% CI: 10.1–NR) (p = 0.97), respectively. No significant differences in the incidence of cytokine release syndrome (p = 0.53) or grade ≥3 neurotoxicity (p = 0.56) were observed. Relapse and nonrelapse mortality were not significantly different between both groups. Our findings provide additional support that CAR‐T cell therapy is feasible and effective in patients with r/r DLBCL aged 70 years or older, demonstrating outcomes comparable to those observed in younger patients. CAR‐T cell therapy should be not withheld for elderly patients with r/r DLBCL. |
| first_indexed | 2024-04-24T16:36:47Z |
| format | Article |
| id | doaj.art-05d6d035219c46dfa19febde67f0fda6 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-04-24T16:36:47Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-05d6d035219c46dfa19febde67f0fda62024-03-29T14:20:28ZengWileyHemaSphere2572-92412024-03-0183n/an/a10.1002/hem3.54Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort studyPhilipp Berning0Evgenii Shumilov1Markus Maulhardt2Hristo Boyadzhiev3Andrea Kerkhoff4Simon Call5Christian Reicherts6Anna O. Saidy7Enver Aydilek8Michèle Hoffmann9Urban Novak10Michael Daskalakis11Norbert Schmitz12Matthias Stelljes13Gerald Wulf14Ulrike Bacher15Georg Lenz16Thomas Pabst17Department of Hematology and Oncology University Hospital Muenster Muenster GermanyDepartment of Hematology and Oncology University Hospital Muenster Muenster GermanyDepartment of Hematology and Medical Oncology University Hospital Göttingen Göttingen GermanyDepartment of Medical Oncology, University Hospital Bern University of Bern Bern SwitzerlandDepartment of Hematology and Oncology University Hospital Muenster Muenster GermanyDepartment of Hematology and Oncology University Hospital Muenster Muenster GermanyDepartment of Hematology and Oncology University Hospital Muenster Muenster GermanyDepartment of Hematology, Oncology, and Tumor Immunology Helios Klinikum Berlin‐Buch Berlin GermanyDepartment of Hematology and Medical Oncology University Hospital Göttingen Göttingen GermanyDepartment of Medical Oncology, University Hospital Bern University of Bern Bern SwitzerlandDepartment of Medical Oncology, University Hospital Bern University of Bern Bern SwitzerlandDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital University of Bern Bern SwitzerlandDepartment of Hematology and Oncology University Hospital Muenster Muenster GermanyDepartment of Hematology and Oncology University Hospital Muenster Muenster GermanyDepartment of Hematology and Medical Oncology University Hospital Göttingen Göttingen GermanyDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital University of Bern Bern SwitzerlandDepartment of Hematology and Oncology University Hospital Muenster Muenster GermanyDepartment of Medical Oncology, University Hospital Bern University of Bern Bern SwitzerlandAbstract CD19‐directed chimeric antigen receptor (CAR)‐T cell therapy has become a standard treatment for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). While the benefits of CAR‐T cell treatment are clear in the general patient population, there remains a relative scarcity of real‐world evidence regarding its efficacy and toxicity in patients (pts) aged ≥70 years with DLBCL. We conducted a multicenter retrospective analysis including 172 r/r DLBCL pts with CAR‐T cell treatment, axicabtagene ciloleucel or tisagenlecleucel, between 2019 and 2023 at three tertiary centers. Pts were grouped by age at CAR‐T infusion (<70 vs. ≥70 years). Subsequently, descriptive and survival analyses, including propensity score matching, were performed to compare outcomes between both age groups. We identified 109 pts aged <70 and 63 pts aged ≥70 years. Overall response rates for both age groups were comparable (77.7% vs. 78.3%; p = 0.63). With a median follow‐up of 8.3 months, median progression‐free survival was 10.2 months (95% confidence interval [CI]: 6.5–21.8) and 11.1 months (95% CI: 4.9–NR) (p = 0.93) for both cohorts. Median overall survival reached 21.8 months (95% CI: 11.8–NR) and 34.4 months (95% CI: 10.1–NR) (p = 0.97), respectively. No significant differences in the incidence of cytokine release syndrome (p = 0.53) or grade ≥3 neurotoxicity (p = 0.56) were observed. Relapse and nonrelapse mortality were not significantly different between both groups. Our findings provide additional support that CAR‐T cell therapy is feasible and effective in patients with r/r DLBCL aged 70 years or older, demonstrating outcomes comparable to those observed in younger patients. CAR‐T cell therapy should be not withheld for elderly patients with r/r DLBCL.https://doi.org/10.1002/hem3.54 |
| spellingShingle | Philipp Berning Evgenii Shumilov Markus Maulhardt Hristo Boyadzhiev Andrea Kerkhoff Simon Call Christian Reicherts Anna O. Saidy Enver Aydilek Michèle Hoffmann Urban Novak Michael Daskalakis Norbert Schmitz Matthias Stelljes Gerald Wulf Ulrike Bacher Georg Lenz Thomas Pabst Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study HemaSphere |
| title | Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study |
| title_full | Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study |
| title_fullStr | Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study |
| title_full_unstemmed | Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study |
| title_short | Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study |
| title_sort | chimeric antigen receptor t cell therapy shows similar efficacy and toxicity in patients with diffuse large b cell lymphoma aged 70 and older compared to younger patients a multicenter cohort study |
| url | https://doi.org/10.1002/hem3.54 |
| work_keys_str_mv | AT philippberning chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT evgeniishumilov chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT markusmaulhardt chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT hristoboyadzhiev chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT andreakerkhoff chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT simoncall chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT christianreicherts chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT annaosaidy chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT enveraydilek chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT michelehoffmann chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT urbannovak chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT michaeldaskalakis chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT norbertschmitz chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT matthiasstelljes chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT geraldwulf chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT ulrikebacher chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT georglenz chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy AT thomaspabst chimericantigenreceptortcelltherapyshowssimilarefficacyandtoxicityinpatientswithdiffuselargebcelllymphomaaged70andoldercomparedtoyoungerpatientsamulticentercohortstudy |